Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Salesforce

Cisco Systems

Disney

Home Depot

Coca-Cola

NIKE

Companies in the Dow "tend to be boring, mature companies that typically pay nice dividends," the "Mad Money" host said.

Jim Cramer picks 7 Dow stocks that investors should consider owning

Gilead Sciences

Eli Lilly

Regeneron Pharmaceuticals

UnitedHealth Group

Could health care stocks be the best stocks to jump on in the second half of 2022?

What Stocks To Buy Today? 5 Health Care Stocks To Know

AstraZeneca

Pfizer

Roche Holding AG

Sanofi

Health care investors would be wise to keep tabs on the results of numerous drug trials scheduled to be revealed in the third quarter. Trial data can impact the stock price of a pharmaceutical company, sometimes sending it up, sometimes down.

3rd-Quarter Clinical Trial Data Could Shake Up Pharma Stocks

Broadcom

Crescent Capital BDC Inc

FS KKR Capital Corp

Hasbro

Raytheon Technologies

These stocks pay dividends, have low payout ratios, low P/E multiples, and good growth. These six stocks are in industries and fields that make them recession-proof stocks, especially given their dividend yields and low multiples.

6 Recession-Proof Stocks to Buy as the Market Boom Ends

Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Merck (MRK) Could Beat Earnings Estimates Again

Bayer AG

Loncar Cancer Immunotherapy ETF

Seagen

Oncology remains the fastest growing pharma segment, where innovation is largely driven by emerging small companies. The global oncology market is estimated at c US$175–180bn and is anticipated to more than double from current levels within the next seven years to address the rising incidence rates.

Oncology ABCs: A Small-Cap Biopharma Prospectus Series

Aurinia Pharmaceuticals

The most recent two hottest potatoes in the biotech arena are Aurinia Pharmaceuticals and Seagen. While the latter is mostly/recently associated with an upcoming Merck buyout, the former has been associated with many big pharma names.

A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)

American Electric Power Company

Campbell Soup

Hershey

Lockheed Martin

We have narrowed our search to five large-cap, low-beta stocks with a solid dividend yield. These are: HSY, LMT, MRK, AEP and CPB.

Q3 Likely to Remain Volatile: Top 5 Picks to Stay Safe

Chevron

Amgen

Johnson & Johnson

Travelers

The U.S. stock market had a rough start to 2022 with a market correction hitting stocks and many indexes seeing their worst performances in decades. What Happened: The S&P 500, as tracked by the SPDR S&P 500 ETF Trust (ARCA:SPY), saw a decline of 20.8% in the first half of 2022.

Only 8 Of The 30 Dow Jones Stocks Were Positive In The First Half Of 2022: Chevron Leads, But Who Else Was Up?

Medical Properties Trust

Investors may want to consider the stocks in this article, in my view, since they meet the following value criteria:

3 Stocks With Solid Records of Sales and Earnings Growth

Here is how Merck (MRK) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.

Has Merck & Co. (MRK) Outpaced Other Medical Stocks This Year?

Merck (MRK) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Why Merck (MRK) Is a Great Growth Stock

Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and a solid pipeline are some key reasons to own Merck's (MRK) stock.

4 Reasons Why Investors Should Buy Merck (MRK) Stock Now

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Merck (MRK) is a Top-Ranked Value Stock: Should You Buy?

It could unlock some tremendous growth potential for the healthcare giant.

This Acquisition Could Make Merck a Scorching-Hot Buy

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to Market

Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to Market

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2022 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. ET on Thursday, July 28. During the call, company executives will provide an overview of Merck's performance for the quarter and outlook. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, alo

Merck to Hold Second-Quarter 2022 Sales and Earnings Conference Call July 28

AbbVie

Bristol-Myers

Novartis

Investors who are sweating the loss of patent protection for some of Big Pharma's top-selling drugs should relax.

Investors Need Not Be Alarmed by Drug Patent Expirations

Merck & Co., Inc.'s (NYSE:MRK) recent breakout above the $88 level took out both its 2021 and 2000 highs.

Why Call Traders Should Consider Merck Stock

European Commission approves Merck's (MRK) Keytruda as an adjuvant treatment for adults and adolescent patients with stage IIB or IIC melanoma and who have undergone complete resection.

Merck (MRK) Keytruda Gets Europe Nod for Expanded Melanoma Use

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA® Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer

LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer

Seagen had two setbacks this year - the below-consensus FY2022 guidance and the resignation of CEO Siegall. The stock shot up this month when rumors surfaced that Merck is interested in acquiring the company.

Seagen Would Be A Great Fit For Merck

Darden Restaurants

FedEx

J. M. Smucker

Do these dividend stocks have a place in your portfolio right now?

4 Top Dividend Stocks To Watch Amid Recession Concerns

These stocks offer attractive dividends that investors should be able to count on.

3 Top Dividend Stocks for Generating Passive Income

McDonald's

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Investors can find safety from the bear market in these three Dow stocks. They offer low volatility, stable dividends and outperformance.

News for Merck Stock (MRK)